Behavioural effects of oral cannabidiol (CBD) treatment in the superoxide dismutase 1 G93 A (SOD1G93 A) mouse model of amyotrophic lateral sclerosis
Thus, the current remedial oral dose of CBD delayed disease progression (inferred by bodyweight) in both male and female mice and improve specific cognitive deficits of SOD1<sup>G93A</sup> mice in a sex specific manner without altering the motor phenotype.
Authors
- Rossana Rosa Porto (ORCID: https://orcid.org/0000-0002-7292-6756)
- Samiksha Ghimire (ORCID: https://orcid.org/0000-0002-6028-1460)
- Lyndsey L. Anderson (ORCID: https://orcid.org/0000-0002-0037-0891)
- Fabian Kreilaus
- Justin J. Yerbury (ORCID: https://orcid.org/0000-0003-2528-7039)
- Jonathon Carl Arnold (ORCID: https://orcid.org/0000-0002-0159-9997)
- Tim Karl (ORCID: https://orcid.org/0000-0001-9904-8482)
Institutions
- Camden and Campbelltown Hospitals (AU)
- The University of Sydney (AU)
- University of Wollongong (AU)
- Illawarra Health and Medical Research Institute (AU)
- Western Sydney University (AU)
Publication Details
- Journal
- Psychopharmacology
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1007/s00213-025-06785-z
- Citations
- 1
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Western Sydney University